SOHM, a pharma-biotech firm specializing in generic drugs and gene-editing solutions, has announced plans to expand into biotechnology-driven cosmeceuticals as part of its long-term growth strategy. The company is establishing a dedicated biotech division to support the development of advanced skincare products utilizing biologically sourced ingredients and modern bioprocessing methods. Dr. Lucia Piccotti, a Board Member of SOHM’s Health Advisory Board, stated, “We see biotechnology as a powerful tool to enhance the quality and performance of skin care. This strategic expansion builds directly on our legacy in health and wellness products while allowing us to lead in a new era of scientifically driven cosmeceuticals.”
The initiative will explore new skincare formulations using exosomes, peptides, and regenerative proteins, along with cell culture and fermentation techniques to produce high-purity cosmetic ingredients. SOHM’s approach also includes advanced delivery systems designed to improve stability and bioactivity. According to Piccotti, “This is not a departure from who we are—it’s the next step forward. With the support of our biotech division, we aim to develop a new class of premium skincare solutions that reflect both our heritage and our future.” The expansion aligns with SOHM’s broader plan to focus on innovation, intellectual property, and global market opportunities in the health and wellness sector.
